Coya Therapeutics reported a net margin of -2,723.44% for the quarter ended Jun 2026. These financial ratios cover 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||
| EBT Margin | 30.24% | -3,982.96% | -84.42% | -209,031.51% | -2,833.35% | -3,725.17% | -68.26% | -152.30% | -2,869.63% | -2,723.44% | |||||
| EBIT Margin | 30.24% | -4,322.84% | -94.48% | -209,031.51% | -2,976.89% | -3,920.47% | -68.26% | -152.30% | -3,042.13% | -2,891.13% | |||||
| EBITDA Margin | 30.36% | -4,317.45% | -94.28% | -208,681.10% | -2,974.24% | -3,916.29% | -68.07% | -152.12% | -3,041.01% | -2,889.98% | |||||
| Operating Margin | 30.24% | -4,322.84% | -94.48% | -209,031.51% | -2,976.89% | -3,920.47% | -68.26% | -152.30% | -3,042.13% | -2,891.13% | |||||
| Net Margin | 30.24% | -3,982.96% | -84.42% | -209,031.51% | -2,833.35% | -3,725.17% | -68.26% | -152.30% | -2,869.63% | -2,723.44% | |||||
| FCF Margin | -37.34% | 1,691.82% | -133.23% | -123,451.18% | -1,096.72% | -3,528.56% | -31.72% | -25.43% | -2,472.07% | -3,026.08% | |||||
| Efficiency | |||||||||||||||
| Assets AverageAssets Avg. | 12.91M | 15.94M | 13.18M | 26.58M | 39.33M | 38.67M | 37.75M | 39.95M | 41.38M | 35.93M | 32.75M | 41.00M | 51.61M | 50.29M | |
| Asset Utilization RatioAsset Util. | 0.23 | 0.16 | 0.25 | 0.25 | 0.09 | 0.09 | 0.01 | 0.12 | 0.19 | 0.15 | 0.16 | ||||
| Valuation | |||||||||||||||
| Price to EarningsP/E | -6.13 | -13.62 | -12.44 | -10.72 | 41.49 | -28.69 | -31.90 | -22.06 | -23.46 | -14.81 | -15.78 | -39.23 | -16.09 | -12.82 | -20.67 |
| Price to SalesP/S | 12.55 | 0.00M | 26.93 | 0.05M | 419.61 | 587.77 | 26.78 | 24.50 | 368.00 | 563.00 | |||||
| Price to BookP/B | -1.46 | 2.45 | 3.06 | 3.79 | 2.11 | 4.48 | 2.62 | 3.07 | 2.42 | 3.24 | 3.40 | 3.50 | 2.26 | 1.89 | 3.17 |
| Enterprise Value | 6.34M | 23.17M | 27.39M | 27.31M | 42.69M | 108.96M | 55.64M | 67.08M | 57.39M | 72.68M | 66.37M | 67.30M | 50.21M | 41.70M | 94.03M |
| EV to EBIT | -3.17 | -7.99 | -8.42 | -7.66 | 23.52 | -19.87 | -17.19 | -15.07 | -14.07 | -9.47 | -10.35 | -27.66 | -8.33 | -5.46 | -13.34 |
| EV to EBITDA | -3.18 | -8.01 | -8.43 | -7.68 | 23.43 | -19.90 | -17.23 | -15.10 | -14.09 | -9.48 | -10.36 | -27.74 | -8.34 | -5.46 | -13.35 |
| Market Capitalization | 12.28M | 39.49M | 40.49M | 38.20M | 75.31M | 144.96M | 92.24M | 98.18M | 95.73M | 108.21M | 96.17M | 95.43M | 97.04M | 92.42M | 137.23M |
| Price to FCFP/FCF | -5.52 | -10.22 | -14.12 | -17.24 | -33.61 | 67.55 | -20.21 | -17.98 | -39.73 | -38.26 | -16.66 | -84.41 | -96.35 | -14.89 | -18.60 |
| EV to FCF | -2.85 | -6.00 | -9.55 | -12.33 | -19.05 | 50.78 | -12.19 | -12.28 | -23.82 | -25.70 | -11.50 | -59.53 | -49.86 | -6.72 | -12.75 |
| EV to CFO | -2.85 | -6.00 | -9.55 | -12.33 | -19.05 | 50.78 | -12.19 | -12.28 | -23.82 | -25.70 | -11.50 | -59.53 | -49.86 | -6.72 | -12.75 |
| Return Ratios | |||||||||||||||
| Return on Sales [ROS]ROS | 30.24% | -4,322.84% | -94.48% | -118.84% | -209,031.51% | -2,976.89% | -3,920.47% | -68.26% | -152.30% | -3,042.13% | -2,891.13% | ||||
| Return on Capital Employed [ROCE]ROCE | -94.60% | -73.49% | -103.04% | -36.71% | -29.95% | -30.05% | -32.05% | -47.75% | -52.50% | -71.98% | -70.85% | -64.21% | -46.85% | -49.49% | |
| Return on Assets [ROA]ROA | -85.31% | -67.86% | -88.92% | -29.74% | -25.57% | -25.07% | -28.03% | -41.24% | -45.27% | -61.04% | -60.81% | -53.34% | -42.17% | -44.36% |